Amgen to build new research and development facility in Thousand Oaks, California, costing over $600 million. The facility is not for manufacturing but will allow collaboration for next-generation drugs. Construction begins in Q3, creating hundreds of U.S. jobs. Amgen has invested nearly $5 billion in U.S. capital expenditures since 2017. CEO Bob Bradway highlights commitment to American science and innovation.

Read more at CNBC: Amgen to invest $600 million in new R&D facility in California